NASDAQ: GYREGyre Therapeutics Inc Stock
$20.77+2.49 (+13.62%)
Updated Dec 8, 2023
GYRE Price
$20.77
Fair Value Price
N/A
Market Cap
$52.59M
52 Week Low
$2.83
52 Week High
$27.39
P/E
-1x
P/B
14.95x
P/S
N/A
PEG
N/A
Dividend Yield
16.18%
Revenue
$0.00
Earnings
-$44.24M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
1.83
Operating Cash Flow
-$13M
Beta
1.17
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
GYRE Overview
Catalyst Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing protease product candidates in the fields of hemostasis and complement regulation. The company's protease engineering platform creates improved or novel molecules to treat diseases that result from dysregulation of the complement system. It develops CB 2782-PEG, a component 3 (C3) degrader for the treatment of dry age-related macular degeneration (dAMD); and CB 4332 for patients with deficiencies in complement factor I (CFI), including dAMD. The company also develops ProTUNE C3b/C4b degrader and ImmunoTUNE C3a/C5a degrader platforms designed to target other disorders of the complement or inflammatory pathways. It has a strategic research collaboration with Mosaic Biosciences, Inc.; and license and collaboration agreement with Biogen International GmbH. Catalyst Biosciences, Inc. was founded in 2002 and is headquartered in South San Francisco, California.
Zen Score
–
Industry Average (26)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how GYRE scored across 38 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
GYRE is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
GYRE is poor value based on its book value relative to its share price (14.95x), compared to the US Biotechnology industry average (5.42x)
P/B vs Industry Valuation
GYRE is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 35 more GYRE due diligence checks available for Premium users.
Be the first to know about important GYRE news, forecast changes, insider trades & much more!
GYRE News
Valuation
GYRE fair value
Fair Value of GYRE stock based on Discounted Cash Flow (DCF)
Price
$20.77
Fair Value
$0.72
Overvalued by
2,766.73%
GYRE is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
GYRE price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1x
Industry
11.7x
Market
31.32x
GYRE price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
14.95x
Industry
5.42x
GYRE is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
GYRE's financial health
Profit margin
Revenue
$0.0
Net Income
-$1.6M
Profit Margin
0%
GYRE's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$10.0M
Liabilities
$6.4M
Debt to equity
1.83
GYRE's short-term assets ($5.13M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
GYRE's short-term assets ($5.13M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
GYRE's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
GYRE's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$3.2M
Investing
$0.0
Financing
-$1.5M
GYRE's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
GYRE vs Biotech Stocks
Gyre Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.